© MAR 2022 | IRE Journals | Volume 5 Issue 9 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV5I9-1722189

The Enzymatic Gatekeepers of Glycemic Flux: Revisiting α-Amylase and α-Glucosidase Inhibition as a Cornerstone of Integrative Diabetes Management

BADA, SUNDAY O.
Biochemistry and Toxicology Unit, Department of Science Laboratory Technology, Rufus Giwa Polytechnic, Owo, Ondo State, Nigeria

Abstract - Type 2 Diabetes Mellitus (T2DM) has emerged as one of the most significant public health crises of the 21st century, primarily characterized by postprandial hyperglycemia resulting from impaired insulin dynamics. A key therapeutic strategy is to slow carbohydrate digestion by inhibiting α-amylase and α-glucosidase. This study examines the structural biochemistry of these enzymes and evaluates the efficacy of current pharmacological inhibitors, including acarbose, miglitol, and voglibose. Projections indicate a global prevalence of 7,079 cases per 100,000 population by 2030, necessitating more effective and safer therapeutic interventions. Using in vitro enzymatic assays, including the dinitrosalicylic acid method and p-nitrophenyl glucopyranoside (pNPG) analysis, we investigate the inhibitory potential of both synthetic and natural compounds. The research shows that while synthetic inhibitors effectively reduce HbA1c by 0.5–1.4%, significant gastrointestinal side effects limit their use. Natural phytochemicals, such as rosmarinic acid and eriodictyol, exhibit higher binding affinities in molecular docking studies than acarbose, offering a promising, milder inhibitory approach. This comprehensive review consolidates the current understanding of enzyme inhibition as a cornerstone of glucose homeostasis management.

Keywords: Type 2 Diabetes Mellitus, α-Amylase, α-Glucosidase, Acarbose, Phytochemicals, Rosmarinic Acid, Molecular Docking, Postprandial Hyperglycemia, Enzyme Inhibition.

I. INTRODUCTION

1.1 Global Epidemiology and the T2DM Crisis

The global burden of Type 2 Diabetes Mellitus is escalating at an unprecedented rate, placing immense strain on healthcare systems worldwide [1]. By 2018, the number of prevalent cases exceeded 500 million, with estimates indicating that prevalence is comparable across high- and low-income nations [2]. However, the most rapid growth is observed in lower-income regions and developing economies [2]. For instance, in Indonesia, prevalence rose from 4,285 per 100,000 in 2019 to over 6,054 per 100,000 in 2021 [3]. These statistics underscore the critical need for accessible, low-cost management strategies focused on dietary intervention and enzymatic control [4]. In particular, targeting the catalytic activity of α-amylase and α-glucosidase provides a mechanistic pathway to attenuate postprandial glucose excursions, which are pivotal in the pathogenesis of chronic diabetic complications such as nephropathy and retinopathy [5]. These digestive enzymes facilitate the hydrolysis of complex polysaccharides into absorbable monosaccharides within the small intestinal lumen, thereby significantly elevating postprandial blood glucose levels [6]. Accordingly, modulating these enzymatic activities has emerged as a key prophylactic target for improving glycemic control and preventing the systemic complications associated with diabetes mellitus [7].

1.2 The Role of Postprandial Hyperglycemia

Postprandial hyperglycemia—the rapid spike in blood glucose following a meal—is a major contributor to the development of chronic diabetic complications, including cardiovascular disease, retinopathy, and neuropathy [8]. In healthy individuals, glucose levels are tightly regulated by insulin; however, in T2DM patients, the delayed insulin response allows glucose levels to remain elevated for prolonged periods [9]. Controlling these spikes is essential because postprandial glucose levels are often better predictors of cardiovascular morbidity than fasting glucose levels [9]. Inhibiting the carbohydrate-hydrolyzing enzymes -amylase and -glucosidase represents a strategic mechanism to modulate this glycemic flux, effectively delaying the breakdown of polysaccharides into absorbable monosaccharides [10]. Pharmacologically targeting these digestive enzymes offers a reliable method for minimizing the rapid entry of glucose into the systemic circulation, thereby attenuating the

glycemic load [11]. Despite their proven clinical efficacy, traditional synthetic inhibitors like acarbose are frequently associated with gastrointestinal discomfort, including flatulence and abdominal distension, often leading to poor patient compliance [12]. Consequently, there is an urgent research mandate to identify novel, plant-derived inhibitors that demonstrate comparable enzyme-modulating capacity while mitigating these adverse physiological side effects [13]. Investigative efforts are now focused on screening diverse botanical sources for secondary metabolites capable of effectively suppressing enzyme kinetics without inducing the gastrointestinal complications associated with traditional pharmacotherapy [14]. Recent investigations have increasingly utilized molecular docking and in vitro kinetic assays to elucidate the structure-activity relationships of polyphenolic compounds, which exhibit high affinity for the active sites of these digestive enzymes [15]. Beyond simple inhibitory function, these bioactive phytochemicals—including alkaloids, flavonoids, and terpenoids—often exert pleiotropic effects, such as enhancing insulin sensitivity and scavenging reactive oxygen species to alleviate the oxidative stress associated with chronic hyperglycemia [16]. Furthermore, these secondary metabolites demonstrate the potential to harmonize metabolic homeostasis by simultaneously addressing enzymatic dysfunction and cellular oxidative damage [17]. This synergistic mechanism, integrating carbohydrate hydrolysis inhibition with antioxidant-mediated stress reduction, positions natural products as robust alternatives for long-term metabolic control [18]. Accordingly, the present paper critically evaluates the catalytic mechanisms of -amylase and -glucosidase while elucidating the therapeutic promise of phytoconstituents as potent, biocompatible modulators of postprandial glucose metabolism. Furthermore, this assessment examines the comparative efficacy of synthetic therapeutics versus natural lead compounds, with a particular focus on their structural interactions at the enzymatic active site [15].

1.3 Enzymatic Targets: -Amylase and -Glucosidase

Starch digestion begins in the mouth and continues in the small intestine [19]. Human pancreatic α-amylase is an endo-hydrolase that breaks down complex α-1,4-glycosidic linkages in starch and glycogen into smaller fragments, such as maltose and maltotriose [20]. Subsequently, membrane-bound β-glucosidases (maltase, sucrase, isomaltase) at the brush border of the small intestine hydrolyze these oligosaccharides into glucose, which is then absorbed into the portal circulation [21]. Inhibiting these two enzymes slows the rate of glucose production, preventing sharp post-meal peaks in blood sugar [22]. This dual-inhibitory approach is particularly advantageous, as targeting both enzymes concurrently offers a more comprehensive reduction in postprandial glucose levels than single-enzyme inhibition alone [22]. Consequently, exploring phytotherapeutic agents that exhibit synergistic inhibition of these carbohydrate-hydrolyzing enzymes provides a dual-action strategy to modulate postprandial glucose flux [23]. Recent studies emphasize that modulating these pathways through natural inhibitors, such as phenolic compounds, serves as a vital nutritional strategy to dampen starch-to-glucose conversion [20]. Specifically, attenuation of salivary and pancreatic α-amylase activity disrupts the initial breakdown of complex polysaccharides into oligosaccharides [19]. Concurrently, α-glucosidase facilitates the final catalytic stage, converting these disaccharides into monomeric glucose units that readily enter the bloodstream [21]. Consequently, pharmacological blockade of these exo-enzymes prevents the rapid liberation of glucose from the non-reducing termini of dietary substrates [24]. This enzymatic inhibition effectively prolongs the absorption phase of carbohydrate digestion, thereby smoothing postprandial glucose excursions [22] and [21].

1.4 Current Therapeutic Challenges

Currently, Alpha-Glucosidase Inhibitors like acarbose are the only class of drugs that directly target this pathway [25]. While they do not cause hypoglycemia when used as monotherapy, they are associated with high rates of gastrointestinal distress [12]. Approximately 20–30% of patients report symptoms like flatulence, bloating, and diarrhea, which often lead to poor treatment adherence[12]. This has sparked interest in natural products and functional foods that might provide "mild" amylase inhibition and "strong" glucosidase inhibition, a profile believed to reduce side effects while maintaining efficacy [26]. Emerging research suggests that phenolic-rich extracts may offer this nuanced inhibitory balance by modulating substrate-enzyme interactions without the complete blockade

of carbohydrate hydrolysis [27]. Such natural modulators may achieve this effect by exhibiting high binding affinity for intestinal -glucosidase while exerting only a moderate influence on pancreatic -amylase, thereby slowing glucose absorption without causing severe malabsorption or related digestive discomfort [28]. This paradigm shift toward dietary modulation of digestive enzyme kinetics necessitates a deeper understanding of the molecular interactions between specific phytochemical scaffolds and the catalytic sites of these metabolic regulators [29]. Future research must prioritize the systematic evaluation of these phytochemical scaffolds to determine their precise inhibitory kinetics and potential for integration into standardized clinical protocols [30]. Moreover, rigorous validation through in vivo models is essential to confirm that these botanical extracts can effectively mitigate micro- and macrovascular diabetic complications while maintaining a favorable safety profile compared to conventional pharmacological interventions [31]. Furthermore, the transition from traditional bench-top screening to high-throughput bioanalytical techniques, such as ligand fishing, now facilitates the rapid identification of these bioactive ligands within complex plant matrices [32]. By integrating enzyme-immobilized magnetic nanoparticles with high-performance liquid chromatography, researchers can now isolate and characterize potent bioflavonoids that demonstrate superior inhibitory activity compared to standard clinical benchmarks like acarbose [33]. Despite these methodological advancements, establishing a standardized protocol for screening remains critical to mitigate the variability observed in current assays and to ensure the reproducibility of results across different research laboratories [34]. Furthermore, ensuring the quality and pharmacological efficacy of these extracts requires the implementation of standardized methodologies for characterizing active constituents, as the complexity of plant-derived matrices complicates the determination of specific inhibitory profiles [35].

II. LITERATURE REVIEW

2.1 Biochemistry and Structural Biology of Enzymes

2.1.1 Human Pancreatic α-Amylase

HPA (EC 3.2.1.1) is a 56 kDa protein composed of three distinct domains: A, B, and C [36]. The A-domain contains the catalytic $(\beta/\alpha)_8$-barrel, where the active site is located. Structural and kinetic analyses have identified three critical carboxylic acid residues within this site that are essential for the hydrolysis of α-1,4-glycosidic linkages: Asp197, Glu233, and Asp300 [37].

- Asp197: Acts as the nucleophile in the catalytic mechanism; its mutation results in a fold drop in activity [37] and [38].
- Glu233: Serves as the general acid/base catalyst [38].
- Asp300: Essential for orienting the substrate and assisting the nucleophilic water molecule during hydrolysis [37].

The architecture of these catalytic residues dictates the enzyme's substrate specificity and facilitates the precise cleavage of starch into maltose and maltotriose [39]. In contrast, human intestinal -glucosidase, such as the maltase-glucoamylase complex, operates through a distinct catalytic mechanism characterized by a dual-subunit structure that targets the final hydrolysis of oligosaccharides into absorbable glucose [40]. These enzymes utilize a conserved catalytic mechanism involving two essential aspartyl residues, which facilitate the nucleophilic attack required for bond cleavage at the non-reducing terminus of substrates [41] and [42]. These sequential enzymatic processes collectively govern the kinetics of glycemic flux, positioning the gastrointestinal tract as a primary nexus for the metabolic management of Type 2 Diabetes Mellitus [43]and [44].

2.1.2 Human Intestinal Glucosidase

2.1.2 Intestinal α-Glucosidase

α-Glucosidase (EC 3.2.1.20) is an exo-type carbohydrase that catalyzes the release of β-D-glucose from the non-reducing ends of various substrates [45]. Unlike HPA, which is secreted, these enzymes are anchored to the intestinal brush border membrane [46]. Their inhibition is a more direct way to limit the final absorption of glucose into the bloodstream [47] and[48]. The structural diversity of these membrane-bound proteins remains a primary challenge for pharmacological modeling, as their conformational flexibility complicates the design of selective, high-affinity competitive inhibitors [49]. Current efforts are increasingly focused on leveraging these structural insights to identify secondary metabolites that can selectively interact with the enzyme-substrate

complex to modulate catalytic throughput [39]. Comprehensive mapping of these interaction sites, particularly through *in silico* molecular docking and crystallography, is critical to unveiling how structural variations in polyphenolic compounds influence binding affinity and enzyme specificity [50]. Such investigations are particularly vital given that natural inhibitors, such as specific phlorotannins, exhibit distinct competitive and non-competitive binding kinetics against these carbohydrate-hydrolyzing enzymes [51]. Elucidating the precise role of acidic residues, particularly aspartic acid, within these catalytic sites is essential, as these amino acids facilitate crucial intermolecular interactions—including polar, hydrogen, and saline bridging—necessary for enzymatic hydrolysis [52]. For instance, the hydrolysis of glycosidic linkages by these enzymes occurs via the carboxylic acid residues acting as general acid and nucleophile/base, which facilitate reactions with either retention or inversion of the anomeric configuration [46].

2.2 Pharmacological Inhibitors: The Current Clinical Standard

Alpha-Glucosidase Inhibitors are non-insulin medications used primarily for T2DM [53]. Despite their clinical utility in attenuating postprandial hyperglycemia, these synthetic agents are frequently associated with significant gastrointestinal side effects, including bloating and diarrhea, which severely limit patient adherence [54]. Consequently, there is a growing clinical imperative to identify novel, plant-derived bioactive compounds that exert similar hypoglycemic effects while minimizing these adverse metabolic disturbances [55]. Recent investigations have highlighted the potential of polyphenolic compounds, such as phlorotannins, which exhibit robust inhibitory properties against these enzymes by forming hydrogen bonds with active site residues like Asp197 and Glu233 [56]. These natural inhibitors demonstrate superior potency, often achieving significantly lower IC50 values than acarbose in both in vitro assays and diabetic animal models [57].

- Acarbose: A pseudo-tetrasaccharide with very low systemic bioavailability (<2%), acting primarily locally in the gut [58]. It inhibits both -amylase and -glucosidase [59]. While it reduces HbA1c by 0.5–1.0%, its potent amylase inhibition often leads to undigested starch reaching the colon, causing significant flatulence and diarrhea [60].
- Miglitol: A desoxynojirimycin derivative that is almost completely absorbed in the upper intestine [61]. It specifically targets -glucosidase without affecting starch digestion [62].
- Voglibose: An N-substituted derivative of valiolamine that is highly selective for intestinal -glucosidase and is generally better tolerated than acarbose due to its minimal impact on amylase [63].

2.3 Natural and Dietary Inhibitors

The search for natural alternatives has identified numerous compounds with superior docking scores and fewer predicted side effects [64]. Specifically, plant-derived polyphenols have emerged as promising candidates, offering a more nuanced modulation of digestive enzymes compared to synthetic alternatives [65]. These polyphenolic structures, such as flavonoids and phenolic acids, typically stabilize enzyme-inhibitor complexes through precise hydrogen bonding interactions that prevent normal substrate processing [66]. By targeting both α-amylase and α-glucosidase, these secondary metabolites retard starch digestion through enzyme inhibition [67].

- Phytochemical Screening: Studies on *Phaseolus vulgaris* beans have utilized mass spectrometry to identify compounds with significant hypoglycemic activity [68]. For example, studies have identified significant α-glucosidase inhibitory activity in bean cultivars, often exceeding the potency of reference compounds [68].
- Molecular Docking Insights: *In silico* reverse docking has validated several herbal compounds. Rosmarinic acid and eriodictyol exhibit docking scores of -7.9 and -7.4 kcal/mol, respectively, significantly outperforming acarbose's score of -5.2 kcal/mol for HPA [26].
- Non-Phenolic Sources: Food-derived non-phenolic inhibitors, such as certain peptides and organic acids, are being investigated for their ability to guide "diabetes-friendly" recipes by controlling starch digestion rates without extreme enzyme suppression [69].

III. METHODOLOGY

3.1 Preparation of Extracts and Reagents

The extraction of phytochemicals often involves solvents of varying polarity (hexane, ethyl acetate, methanol and water) to isolate specific classes of inhibitors [70].

The dinitrosalicylic acid reagent, crucial for the amylase assay, is prepared by dissolving 1g of 3,5-dinitrosalicylic acid and 30g of sodium-potassium tartrate in 20 mL of 2 M NaOH, eventually diluting to 100 mL [71] and [72]. This solution should be stored in an amber-colored vessel to prevent photodegradation of the reagent components, which may otherwise compromise the accuracy of spectrophotometric absorbance readings.

3.2 α-Amylase Inhibition Assay

Alpha-amylase inhibitory activity is evaluated using a spectrophotometric assay based on the 3,5-dinitrosalicylic acid (DNS) method, which quantifies reducing sugars produced during starch hydrolysis. All reactions are conducted in 100 mM sodium phosphate buffer (pH 6.9) to maintain physiological relevance. Briefly, 1.0 mL of pancreatic amylase solution is pre-incubated with 1.0 mL of the test inhibitor at serial concentrations (10–1000 μg mL^{-1}) for 30 minutes at 25 °C to establish enzyme–inhibitor equilibrium. The enzymatic reaction is initiated by adding a 500 μL aliquot of 1% (w/v) soluble starch prepared in the same buffer. After a 10-minute incubation at 25 °C to allow substrate hydrolysis, the reaction is terminated by adding 1.0 mL of DNS reagent. The mixture is immediately immersed in a boiling water bath for 3.5 minutes to develop color, then cooled to ambient temperature. The resulting chromophore is diluted with 10.0 mL of distilled deionized water, and absorbance is recorded at 540 nm using a UV-Vis spectrophotometer. A control reaction, substituting the inhibitor with an equivalent volume of buffer to represent 100% enzymatic activity, and a blank sample devoid of enzyme are processed identically. All measurements are performed in triplicate to ensure statistical reliability [73].

3.3 α-Glucosidase Inhibition Assay (pNPG Method)

The α-glucosidase inhibitory activity is assessed using a chromogenic substrate-based assay, employing p-nitrophenyl-α-D-glucopyranoside (pNPG) as the enzymatic substrate. The hydrolysis of pNPG by α-glucosidase liberates p-nitrophenol, which can be quantified spectrophotometrically. All reactions are conducted in 0.1 M potassium phosphate buffer (pH 6.9) to maintain optimal enzymatic activity. In a typical assay, 50 μL of the test inhibitor (prepared at varying concentrations) is mixed with 50 μL of the assay buffer and 100 μL of the enzyme solution, containing α-glucosidase from *Saccharomyces cerevisiae* diluted in the same buffer. Following a brief pre-equilibration period at 37 °C, the enzymatic reaction is initiated by the addition of 50 μL of 5 mM pNPG, yielding a final reaction volume of 250 μL. The mixture is incubated at 37 °C for exactly 5 minutes, after which the reaction is terminated by the addition of 100 μL of 1.0 M sodium carbonate solution, which simultaneously raises the pH to facilitate the quantitative development of the yellow p-nitrophenolate chromophore. The absorbance of the resulting solution is then measured at 405 nm using a microplate spectrophotometer. A negative control (containing buffer in place of the inhibitor) is used to define 100% enzymatic activity, while a blank (containing buffer instead of the enzyme) 1s included to correct for non-enzymatic substrate hydrolysis. Acarbose, a well-established α-glucosidase inhibitor, was employed as a positive reference standard. The percentage inhibition is then calculated. All measurements were performed in triplicate, and the results were expressed as mean ± standard deviation to ensure reproducibility and statistical robustness [74].

IV. RESULTS

4.1 Comparative Values

Table 1 below summarizes the inhibitory potential (IC_{50}) of various natural extracts compared to the standard acarbose. These quantitative benchmarks are determined by calculating the percentage inhibition relative to control absorbance, ensuring standard drug equivalence for comparative analysis [75] and [76].

4.2 Synergistic Effects

Research on combined plant extracts has shown that mixtures often result in higher inhibition than single extracts, and poly-herbal formulations can be optimized for maximum efficacy through synergistic effects [79]. These findings are corroborated by studies demonstrating that the interaction of phytochemicals and starch matrices

plays a crucial role in reducing starch digestibility [80]. Furthermore, this inhibition is frequently quantified as the percentage decrease in product formation, with control samples replacing the bioactive extract with a vehicle such as Dimethyl Sulfoxide to establish baseline enzymatic activity [81].

Furthermore, the standardized determination of inhibitory concentration remains critical for characterizing these synergistic potentials. Specifically, methodologies frequently utilize p-nitrophenyl -D-glucopyranoside (pNPG) as a substrate to quantify -glucosidase activity, where the enzymatic release of p-nitrophenol is halted by alkaline reagents such as NaOH [26]. Specifically, the reaction termination using sodium carbonate or sodium hydroxide at 405 nm effectively quantifies the liberated p-nitrophenol, allowing for robust calculation of the percentage inhibition relative to control samples [82] and [83]. Subsequent determination of these values is typically achieved through linear or non-linear regression analysis of the sample concentration against the observed decrease in absorbance. Furthermore, establishing the dose-response relationship enables the determination of inhibitory efficacy across varying inhibitor concentrations, ensuring that the calculated kinetic constants reflect authentic enzymatic interactions [84]. Moreover, recent investigations into multi-target strategies emphasize the importance of analyzing synergistic interactions, where the combined phytochemical profiles of distinct medicinal species can yield greater enzymatic modulation than individual isolated compounds [85] and [86]. These bioactive secondary metabolites—such as flavonoids and tannins—are recognized as potent inhibitors of carbohydrate-hydrolyzing enzymes [87].

4.3 Kinetic and Molecular Docking Data

Computational studies have investigated the binding interactions of apigenin and rosmarinic acid with various enzymes. Additionally, kinetic evaluations using Lineweaver-Burk plot analysis are used to distinguish between competitive, non-competitive, and mixed-mode inhibition patterns exhibited by these phytochemicals. For instance, non-competitive inhibition profiles indicate that certain herbal constituents bind to allosteric sites, providing a mechanism of action distinct from the active-site blocking characteristic of traditional inhibitors like acarbose [88]. Moreover, comparative kinetic studies demonstrate that while acarbose functions primarily through competitive mechanisms, select medicinal plant constituents exhibit potent mixed-type or non-competitive inhibition, effectively modulating enzyme activity without competing for the active substrate-binding pocket [88]. These distinct kinetic profiles are validated through the analysis of and ratios, which clarify whether the inhibitor alters substrate affinity or reduces the maximum reaction velocity [89]. For instance, studies on specific phenolic acid compounds have demonstrated that increased inhibitor concentrations lead to significant alterations in both and, providing empirical evidence for mixed-type inhibition [90]. Furthermore, molecular simulation studies have corroborated these kinetic findings, revealing that specific flavonoids such as apigenin can bind to allosteric sites near the catalytic region, potentially inducing conformational changes that stabilize the enzyme-inhibitor complex [91]. Such computational insights, when integrated with kinetic analysis, underscore the necessity of experimental validation to correlate docking scores with actual in vitro binding affinity [92]. Advanced molecular modeling techniques, such as GROMACS simulations, have further substantiated these experimental observations by confirming that stable enzyme-inhibitor complexes exhibit favorable root-mean-square deviation values during extended dynamic trajectories [93].

V. DISCUSSION

5.1 Mechanism of Enzyme Suppression

Inhibition of carbohydrate-digesting enzymes effectively flattens the glucose absorption curve [94], although synthetic inhibitors like acarbose can lead to colonic fermentation due to amylase over-inhibition [95]. Natural products such as *Phaseolus vulgaris* and *Phlomis stewartii* may offer a milder amylase inhibitory profile, which is theoretically advantageous for reducing postprandial spikes [96] and [97]. This nuanced inhibitory balance mimics the physiological modulation observed in recent trials of poly-herbal matrices, which demonstrate enhanced potency with reduced side-effect profiles compared to monotherapy [98] and [99]. Specifically, studies have illustrated that such balanced inhibition patterns can be achieved through the combination of various flavonoids, which may display synergistic, additive, or antagonistic effects

depending on the specific enzyme target [100]. Furthermore, determining the binding modes through kinetic parameters such as the Michaelis-Menten constant and maximal velocity facilitates a deeper understanding of how these phytochemicals induce dynamic fluorescence quenching and stabilize enzyme-inhibitor complexes [101]. Molecular dynamics simulations further elucidate these stabilization processes, revealing how specific ligands modulate enzyme conformation over extended time scales [102]. Beyond these temporal dynamics, docking analyses confirm that specific residues—such as Trp 58, Tyr 62, and His 299—serve as critical anchoring points for flavonoid interaction, facilitating stable binding and high inhibitory potency [103]. These docking simulations are frequently validated by the thermodynamic stability of the enzyme-ligand complex, as evidenced by low binding energy values—often below -7.0 kcal/mol—observed with potent phytochemicals like vitexin or stearic acid [104] and [105]. Moreover, in silico screening of extensive phytochemical libraries has proven instrumental in identifying novel lead compounds that exhibit binding affinities comparable to or exceeding those of reference synthetic inhibitors [106]. Consequently, the screening of natural product databases, guided by Lipinski's Rule of Five, has identified numerous promising candidates with robust drug-likeness profiles capable of mitigating postprandial hyperglycemia [107]. Recent empirical research underscores that these synergistic flavonoid mixtures can significantly optimize therapeutic efficacy by targeting multiple amino acid residues, thereby providing more robust metabolic control than single-compound interventions [108].

5.2 Therapeutic Potential of Natural Alternatives

The high correlation between antioxidant activity and enzyme inhibition suggests that phytochemicals provide dual benefits [109]. By reducing oxidative stress while managing glucose, these natural inhibitors may help prevent the long-term vascular complications of diabetes [15]. Moreover, the structural diversity of compounds like flavonoids allows for a wide range of binding affinities. Furthermore, recent systematic analyses have identified numerous unique flavonoid structures that demonstrate potent, dual-target inhibitory efficacy against both α-amylase and α-glucosidase [40]. These therapeutic agents further mitigate hyperglycemic-induced oxidative damage by scavenging free radicals, thereby offering a multifaceted approach to metabolic syndrome management [87] and [109]. Consequently, the integration of these plant-derived inhibitors into therapeutic protocols offers a promising strategy for managing postprandial glucose levels while minimizing the gastrointestinal side effects associated with synthetic agents like acarbose or voglibose [68] and [35]. Furthermore, the development of these nutraceutical alternatives requires rigorous structure-activity relationship profiling, as specific hydroxyl and methoxyl substitutions on the flavonoid backbone significantly modulate binding affinity and enzymatic inhibitory potency [110]. Consequently, characterizing these precise molecular interactions is essential for the design of refined, high-affinity pharmacological agents derived from natural phenolic scaffolds [64] and [111]. Future research should focus on optimizing the bioavailability and pharmacokinetic profiles of these polyphenolic compounds to ensure their clinical efficacy in human subjects [56] and [112]. In this context, computational screening models and quantitative structure-activity relationship analyses are instrumental in streamlining the identification of potent lead compounds by predicting their inhibitory potential against these carbohydrate-hydrolyzing enzymes [113] and [114]. Moreover, the clinical translation of these findings necessitates an evaluation of how various extraction methodologies and solvent polarities influence the recovery of bioactive constituents, as these parameters significantly dictate the resultant therapeutic potential [15] and [35]. Finally, addressing the heterogeneity in in vitro assay methodologies is crucial, as variable substrate sources and enzyme origins currently impede the reproducibility of standardized inhibitory data across experimental studies [40]. To overcome these challenges, adopting standardized protocols for characterizing the synergistic interactions of multi-component extracts will be essential to accurately reflect the complex metabolic modulation required for effective long-term glycemic control [115]. Furthermore, advancing these methodologies will facilitate a transition from exploratory screening to the development of standardized nutraceuticals, ultimately providing a safer, sustainable clinical approach to postprandial glucose regulation [39] and [41]. However, given that food-derived inhibitors often display lower potency than synthetic

pharmaceuticals, they are best positioned as complementary strategies rather than replacements for current standards of care [116]. Integrating these dietary interventions with clinical pharmacotherapy warrants deeper exploration into the influence of food matrices, as complex interactions between polyphenols and milk proteins or lipids can fundamentally alter the bioavailability and binding kinetics of the active compounds [117] and [118].

VI. CONCLUSION

The present findings reaffirm the therapeutic centrality of α-amylase and α-glucosidase as molecular targets in the management of type 2 diabetes mellitus (T2DM). While acarbose remains a benchmark pharmacological inhibitor, its clinical utility is considerably constrained by dose-dependent gastrointestinal adverse effects, underscoring the pressing need for more tolerable and safer therapeutic alternatives. In this context, phytochemical-rich matrices derived from legumes and medicinal plants represent a compelling reservoir of candidate inhibitors, offering favorable safety profiles and pleiotropic bioactivities.

However, the translational trajectory from promising *in vitro* bioactivity to demonstrable *in vivo* clinical efficacy remains fraught with substantial challenges, necessitating rigorously designed, standardized interventional trials. Paramount among these prerequisites are the systematic evaluation of polyherbal synergistic interactions, comprehensive long-term toxicological profiling, and the elucidation of specific binding kinetics, allosteric regulatory mechanisms, and downstream metabolic perturbations governing enzyme inhibition. Moreover, the marked inter-study variability currently plaguing natural product research mandates the development of universally accepted analytical protocols—encompassing standardized extraction procedures, uniform assay conditions, and validated reference controls—to ensure inter-laboratory reproducibility and clinical concordance.

Ultimately, this line of inquiry heralds a pivotal paradigm shift away from purely symptomatic pharmacotherapy and toward precision-oriented, nutritionally integrated dietary strategies that exploit targeted enzymatic modulation to achieve glycemic homeostasis. Realizing this transformative vision requires not only a deeper mechanistic dissection of how individual bioactive compounds perturb carbohydrate-metabolizing networks but also a holistic appraisal of their dynamic interplay when co-administered with established synthetic agents. Such integrative approaches may furnish the foundational evidence necessary to elevate these natural compounds from experimental curiosities to validated adjunctive therapeutics, thereby fundamentally reshaping the dietary management of chronic hyperglycemia and, more broadly, the metabolic syndrome continuum.

Table 1

Inhibitor Source	Enzyme	Value	References
Acarbose	α-Amylase	37.25	[77]
Acarbose	α-Glucosidase	33.29	[77]
Phlomis stewartii	α-Amylase	51.03	[77]
Phlomis stewatii	α-Glucosidase	N/A	[77]
Cannellino Rosso Bean	α-Amylase	25.9 mg/mL	[68]
Cannellino Rosso Bean	α-Glucisidase	4.0 mg/mL	[68]
Poly-herbal Extract	α-Amylase	Not reported	[78]

[Amylase IC_{50} (mug/mL) and Glucosidase IC_{50} (mug/mL)]

REFERENCES

[1] Ye, J., Wu, Y., Yang, S., Zhu, D., Chen, F., Chen, J., Ji, X., & Hou, K. (2023). The global, regional and national burden of type 2 diabetes mellitus in the past, present and future: a systematic analysis of the Global Burden of Disease Study 2019. *Frontiers in Endocrinology*, *14.*

[2] Kaiser, A. B., Zhang, N., & Pluijm, W. van der. (2018). Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028). *Diabetes, 67*

[3] Chen, X., Lin, H., Wu, Y., Wang, M.-F., Lin, S., & Huang, J. (2025). The impact of the COVID-19 pandemic on the global burden of type 2 diabetes: a study based on GBD 2021 data. *Frontiers in Endocrinology*, *16.*

[4] Khan, F., Khan, M. V., Kumar, A., & Akhtar, S. (2024). Recent Advances in the Development of Alpha-Glucosidase and Alpha-Amylase Inhibitors in Type 2 Diabetes Management: Insights from In silico to In vitro Studies. *Current Drug Targets*, *25 (12), 782–795.*

[5] Son, B. H., Nga, V. V., Hong, L. T., & Quỳnh, Đ. T. (2022). Potent Natural Inhibitors of Alpha-Glucosidase and the Application of Aspergillus spp. in Type 2 Diabetes Drugs: a Review. *VNU Journal of Science Medical and Pharmaceutical Sciences*, *38*(1).

[6] Sadeghi, M., Miroliaei, M., Ghanadian, M., & Taslimi, P. (2024). The Inhibitory Potential of Natural Compounds on α-Amylase and α-Glucosidase in the Management of Type 2 Diabetes. *SHILAP Revista de Lepidopterología*.

[7] Gong, L., Feng, D., Wang, T., Ren, Y., Liu, Y., & Wang, J. (2020). Inhibitors of α-amylase and α-glucosidase: Potential linkage for whole cereal foods on prevention of hyperglycemia. *Food Science & Nutrition*, *8*(12), 6320–6337.

[8] Kumar, V., Prakash, O., Kumar, S., & Narwal, S. (2011). α-glucosidase inhibitors from plants: A natural approach to treat diabetes. *Pharmacognosy Reviews/Bioinformatics Trends/Pharmacognosy Review*, *5*(9), 19–19.

[9] Node, K., & Inoue, T. (2009). Postprandial hyperglycemia as an etiological factor in vascular failure. *Cardiovascular Diabetology*, *8(1),* 23–23.

[10] Kashtoh, H., & Baek, K. (2022). Recent Updates on Phytoconstituent Alpha-Glucosidase Inhibitors: An Approach towards the Treatment of Type Two Diabetes. *Plants*, *11*(20), 2722–2722.

[11] Tshiyoyo, K., Bester, M. J., Serem, J. C., & Apostolides, Z. (2022). In silico reverse docking and in-vitro studies identified curcumin, 18α-glycyrrhetinic acid, rosmarinic acid, and quercetin as inhibitors of α-glucosidase and pancreatic α-amylase and lipid accumulation in HepG2 cells, important type 2 diabetes targets. *Journal of Molecular Structure*, *1266,* 133492–133492.

[12] Stein, S. A., Lamos, E. M., & Davis, S. N. (2012). A review of the efficacy and safety of oral antidiabetic drugs. *Expert Opinion on Drug Safety*, *12*(2), 153–175.

[13] Mamri, S., Daoudi, N. E., BARAICH, A., Ouahhoud, S., Khoulati, A., Choukri, M., Asehraou, A., Bnouham, M., Jaouadi, B., Abousalham, A., Dabiellil, F., Salamatullah, A. M., & Saalaoui, E. (2024). Comprehensive analysis of bioactive compounds in Crocus sativus stamens extracts by HPLC-DAD: investigating antidiabetic activity via in vitro, in vivo, and molecular docking simulation. *Frontiers in Chemistry*, *12,* 1419120–1419120.

[14] Mala, P., Khan, G. A., Gopalan, R. D., Gedefaw, D., & Soapi, K. (2022). Fijian medicinal plants and their role in the prevention of Type 2 diabetes mellitus. *Bioscience Reports*, *42*(11).

[15] Allaoui, H. E., Haboubi, K., Ahmadi, K. E., Bouhrim, M., Elabdouni, A., Eto, B., Shahat, A. A., Herqash, R. N., Bestrioui, M. E., Zouaoui, Z., & Nhiri, M. (2025). Comprehensive assessment of antioxidant, antidiabetic, and anti-glycation properties of aqueous and methanolic extracts from Pistacia lentiscus L. leaves: a potential natural source for managing oxidative stress and diabetes-related complications. *Frontiers in Pharmacology*, *16,* 1551841–1551841.

[16] Shrivastava, M., & Daharia, A. (2026). Plant-Derived Bioactive Compounds as Antidiabetic Agents: Therapeutic Mechanisms and Prospects. *Journal of Pharmacology, Genetics and Molecular Biology*, *vol2. Issue1* 210–27.

[17] Ibrahim, M. A., Koorbanally, N. A., & Islam, Md. S. (2014). Antioxidative Activity and Inhibition of Key Enzymes Linked to Type-2 Diabetes (α-Glucosidase and α-Amylase) by Khaya Senegalensis. *Acta Pharmaceutica*, *64*(3), 311–324.

[18] Assefa, S. T., Yang, E.-Y., Chae, S.-Y., Song, M., Lee, J., Cho, M.-C., & Jang, S. (2019). Alpha Glucosidase Inhibitory Activities of Plants with Focus on Common Vegetables. *Plants*, *9*(1), 2–2.

[19] Ogunyemi, O. M., Gyebi, G. A., Saheed, A. O., Paul, J., Nwaneri-Chidozie, V., Olorundare, O. E., Adebayo, J. O., Koketsu,

M., Aljarba, N. H., Alkahtani, S., Batiha, G. E., & Olaiya, C. O. (2022). Inhibition mechanism of alpha-amylase, a diabetes target, by a steroidal pregnane and pregnane glycosides derived from Gongronema latifolium Benth. *Frontiers in Molecular Biosciences*, *9*, 866719–866719.

[20] Ćorković, I., Gašo-Sokač, D., Pichler, A., Šimunović, J., & Kopjar, M. (2022). Dietary Polyphenols as Natural Inhibitors of α-Amylase and α-Glucosidase. *Life*, *12*(11), 1692–1692.

[21] Maliwal, D., Pissurlenkar, R. R. S., & Telvekar, V. N. (2021). Identification of novel potential anti-diabetic candidates targeting human pancreatic α-amylase and human α-glycosidase: an exhaustive structure-based screening. *TSpace (University of Toronto)*, *100*(5), 338–352.

[22] Lankatillake, C., Luo, S., Flavel, M., Lenon, G. B., Gill, H., Huynh, T., & Dias, D. A. (2021). Screening natural product extracts for potential enzyme inhibitors: protocols and the standardisation of the usage of blanks in α-amylase, α-glucosidase and lipase assays. *Plant Methods*, *17*(1), 3–3.

[23] Alam, F., Shafique, Z., Amjad, S. T., & Asad, M. H. H. B. (2018). Enzyme inhibitors from natural sources with antidiabetic activity: A review. *Phytotherapy Research*, *33*(1), 41–54.

[24] Sapkota, B. K., Khadayat, K., Adhikari, B., Poudel, D. K., Niraula, P., Budhathoki, P., Aryal, B., Basnet, K., Ghimire, M., Marahatha, R., & Parajuli, N. (2021). Phytochemical Analysis, Antidiabetic Potential and in-silico Evaluation of Some Medicinal Plants. *Pharmacognosy Research*, *13*(3), 140–148.

[25] DiNicolantonio, J. J., Bhutani, J., & O'Keefe, J. H. (2015). Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. *Open Heart*, *2*(1).

[26] Tolmie, M., Bester, M. J., & Apostolides, Z. (2021). Inhibition of α-glucosidase and α-amylase by herbal compounds for the treatment of type 2 diabetes: A validation of in silico reverse docking with in vitro enzyme assays. *Journal of Diabetes, 13*(10), 779–791.

[27] 27. Sanna, C., Fais, A., Era, B., Delogu, G., Sanna, E., Dazzi, L., Rosa, A., Marengo, A., Rubiolo, P., Agostini, A. D., Floris, S., & Pintus, F. (2023). Promising inhibition of diabetes-related enzymes and antioxidant properties of *Ptilostemon casabonae* leaves extract. *Journal of Enzyme Inhibition and Medicinal Chemistry, 38*(1), 2274798.

[28] 28. Cisneros-Yupanqui, M., Lante, A., Mihaylova, D., Krastanov, A., & Rizzi, C. (2022). The α-amylase and α-glucosidase inhibition capacity of grape pomace: A review. *Food and Bioprocess Technology, 16*(4), 691–703.

[29] 29. Hogan, S., Zhang, L., Li, J., Sun, S., Canning, C., & Zhou, K. (2010). Antioxidant-rich grape pomace extract suppresses postprandial hyperglycemia in diabetic mice by specifically inhibiting alpha-glucosidase. *Nutrition & Metabolism, 7*(1), 71.

[30] 30. Azmi, N., Azmi, M. N., Babai, M., Bakar, M. H. A., Bakar, M. A., & Omar, M. T. C. (2025). Synthesis and evaluation of para-substituted bis(arylidene)cycloalkanones as potential α-amylase inhibitor with molecular docking and ADMET profiling. *Sains Malaysiana, 54*(9), 2201–2210.

[31] 31. Adisakwattana, S., Ruengsamran, T., Kampa, P., & Sompong, W. (2012). In vitro inhibitory effects of plant-based foods and their combinations on intestinal α-glucosidase and pancreatic α-amylase. *BMC Complementary and Alternative Medicine, 12*(1), 110.

[32] 32. Wubshet, S. G., Brighente, I. M. C., Moaddel, R., & Stærk, D. (2015). Magnetic ligand fishing as a targeting tool for HPLC-HRMS-SPE-NMR: α-Glucosidase inhibitory ligands and alkylresorcinol glycosides from *Eugenia catharinae*. *Journal of Natural Products, 78*(11), 2657–2665.

[33] 33. Ríos, J. L., Francini, F., & Schinella, G. (2015). Natural products for the treatment of type 2 diabetes mellitus. *Planta Medica, 81*, 975–994.

[34] 34. Sales, P. M. de, Souza, P. M., Simeoni, L. A., Magalhães, P. O., & Silveira, D. (2012). α-Amylase inhibitors: A review of raw material and isolated compounds from plant

source. *Journal of Pharmacy & Pharmaceutical Sciences, 15*(1), 141.

[35] 35. Rawal, P., Baral, R., & Panta, S. (2025). In vitro experimental study of aqueous and ethanolic extracts of selected medicinal plants for free radical scavenging and hypoglycemic activity. *Current Perspectives on Medicinal and Aromatic Plants (CUPMAP)*, 36–50.

[36] 36. Brayer, G. D., Luo, Y., & Withers, S. G. (1995). The structure of human pancreatic α-amylase at 1.8 Å resolution and comparisons with related enzymes. *Protein Science, 4*(9), 1730–1742.

[37] 37. Brayer, G. D., Sidhu, G., Maurus, R., Rydberg, E. H., Braun, C., Wang, Y., Nguyen, N. T., Overall, C. M., & Withers, S. G. (2000). Subsite mapping of the human pancreatic α-amylase active site through structural, kinetic, and mutagenesis techniques. *Biochemistry, 39*(16), 4778–4791.

[38] 38. Rydberg, E. H., Li, C., Maurus, R., Overall, C. M., Brayer, G. D., & Withers, S. G. (2002). Mechanistic analyses of catalysis in human pancreatic α-amylase: Detailed kinetic and structural studies of mutants of three conserved carboxylic acids. *Biochemistry, 41*(13), 4492–4502.

[39] 39. Kashtoh, H., & Baek, K.-H. (2023). New insights into the latest advancement in α-amylase inhibitors of plant origin with anti-diabetic effects. *Plants, 12*(16), 2944.

[40] 40. Lam, T.-P., Tran, N.-V. N., Pham, L.-H. D., Lai, N. V.-T., Dang, B.-T. N., Truong, N.-L. N., Nguyen-Vo, S.-K., Hoang, T., Thanh, T., & Tran, T. (2024). Flavonoids as dual-target inhibitors against α-glucosidase and α-amylase: A systematic review of in vitro studies. *Natural Products and Bioprospecting, 14*(1), 4.

[41] 41. Proença, C., Ribeiro, D., Freitas, M., & Fernandes, E. (2021). Flavonoids as potential agents in the management of type 2 diabetes through the modulation of α-amylase and α-glucosidase activity: A review. *Critical Reviews in Food Science and Nutrition, 62*(12), 3137–3207.

[42] 42. Tundis, R., Loizzo, M. R., & Menichini, F. (2010). Natural products as α-amylase and α-glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: An update. *Mini-Reviews in Medicinal Chemistry, 10*(4), 315–331.

[43] 43. Espinoza-Hernández, F. A., Martínez-Medina, S., Mata-Torres, G., Cabello-Hernández, C. A., & Andrade-Cetto, A. (2026). Alternative methods for pharmacological research on the action mechanisms of natural products used in the treatment of type 2 diabetes: A systematic review. *Frontiers in Pharmacology, 17*, 1729030.

[44] 44. Lankatillake, C., Huynh, T., & Dias, D. A. (2019). Understanding glycaemic control and current approaches for screening antidiabetic natural products from evidence-based medicinal plants. *Plant Methods, 15*(1), 105.

[45] 45. Al-Bedak, O. A. H., Sakr, R. S., & AL-Kolaibe, A. M. (2022). The microbial amylases: An overview with practical consequences and applications. *Journal of Microbiology & Experimentation, 10*(4), 130–134.

[46] 46. Elferink, H., Bruekers, J. P. J., Veeneman, G. H., & Boltje, T. J. (2020). A comprehensive overview of substrate specificity of glycoside hydrolases and transporters in the small intestine. *Cellular and Molecular Life Sciences, 77*(23), 4799–4826.

[47] 47. Adefegha, S. A. (2013). Phytochemistry and mode of action of some tropical spices in the management of type-2 diabetes and hypertension. *African Journal of Pharmacy and Pharmacology, 7*(7), 332–346.

[48] 48. Bhuyan, P., Ganguly, M., Baruah, I., Borgohain, G., Hazarika, J., & Sarma, S. (2022). Alpha-glucosidase inhibitory properties of a few bioactive compounds isolated from black rice bran: Combined in vitro and in silico evidence supporting the antidiabetic effect of black rice. *RSC Advances, 12*(35), 22650–22661.

[49] 49. Topuz, S., Demir, K., & Alıcı, H. (2025). Unraveling the dynamic landscape of α-glucosidase: A molecular dynamics approach to enzyme stability and function. *South African Journal of Chemistry, 79*, 107–116.

[50] 50. Riyaphan, J., Pham, D., Leong, M. K., & Weng, C. (2021). In silico approaches to identify polyphenol compounds as α-

glucosidase and α-amylase inhibitors against type-II diabetes. *Biomolecules, 11*(12), 1877.

[51] 51. Erpel, F., Mateos, R., Pérez-Jiménez, J., & Pérez-Correa, J. R. (2020). Phlorotannins: From isolation and structural characterization to the evaluation of their antidiabetic and anticancer potential. *Food Research International, 137*, 109589.

[52] 52. Zimmet, P., Alberti, K. G. M. M., & Shaw, J. E. (2001). Global and societal implications of the diabetes epidemic. *Nature, 414*(6865), 782–787.

[53] 53. Mohajan, D., & Mohajan, H. K. (2024). Alpha-glucosidase inhibitors (AGIs): A new class of oral medication for treatment of type 2 diabetes patients. *Journal of Innovations in Medical Research, 3*(4), 1–6.

[54] 54. Basnet, S., Ghimire, M. P., Lamichhane, T. R., Adhikari, R., & Adhikari, A. (2023). Identification of potential human pancreatic α-amylase inhibitors from natural products by molecular docking, MM/GBSA calculations, MD simulations, and ADMET analysis. *PubMed Central, 18*(3). [Note: Verify original journal; formatted as provided.]

[55] 55. Sadiq, A., Rashid, U., Ahmad, S., Zahoor, M., Alajmi, M. F., Ullah, R., Noman, O. M., Ullah, F., Ayaz, M., Khan, I. A., Islam, Z. U., & Ali, W. (2020). Treating hyperglycemia from *Eryngium caeruleum* M. Bieb: In-vitro α-glucosidase, antioxidant, in-vivo antidiabetic and molecular docking-based approaches. *Frontiers in Chemistry, 8*, 558641.

[56] 56. Salim, R., Nehvi, I. B., Mir, R. A., Tyagi, A., Ali, S., & Bhat, O. M. (2023). A review on anti-nutritional factors: Unraveling the natural gateways to human health. *Frontiers in Nutrition, 10*, 1215873.

[57] 57. Duan, X., Ağar, O. T., Barrow, C. J., Dunshea, F. R., & Suleria, H. A. R. (2023). Improving potential strategies for biological activities of phlorotannins derived from seaweeds. *Critical Reviews in Food Science and Nutrition, 65*(5), 833–855.

[58] 58. Joubert, P. H., Venter, H. L., & Foukaridis, G. N. (1990). The effect of miglitol and acarbose after an oral glucose load: A novel hypoglycaemic mechanism? *British Journal of Clinical Pharmacology, 30*(3), 391–396.

[59] 59. Standl, E., Theodorakis, M. J., Erbach, M., Schnell, O., & Tuomilehto, J. (2014). On the potential of acarbose to reduce cardiovascular disease. *Cardiovascular Diabetology, 13*(1), 81.

[60] 60. Martin, A., & Montgomery, P. A. (1996). Acarbose: An α-glucosidase inhibitor. *American Journal of Health-System Pharmacy, 53*(19), 2277–2290.

[61] 61. Sels, J.-P., Huijberts, M., & Wolffenbuttel, B. H. R. (1999). Miglitol, a new α-glucosidase inhibitor. *Expert Opinion on Pharmacotherapy, 1*(1), 149–156.

[62] 62. Aoki, K., Muraoka, T., Ito, Y., Togashi, Y., & Terauchi, Y. (2010). Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: A crossover study. *Internal Medicine, 49*(12), 1085–1087.

[63] 63. Dabhi, A. S., Bhatt, N., & Shah, M. J. (2013). Voglibose: An alpha glucosidase inhibitor. *Journal of Clinical and Diagnostic Research, 7*(12), 3023–3027.

[64] 64. Rasouli, H., Ghazvini, S. M. B. H., Adibi, H., & Khodarahmi, R. (2017). Differential α-amylase/α-glucosidase inhibitory activities of plant-derived phenolic compounds: A virtual screening perspective for the treatment of obesity and diabetes. *Food & Function, 8*(5), 1942–1954.

[65] 65. Pan, X. (2025). Research progress on polyphenolic substances as α-glucosidase inhibitors. *Academic Journal of Science and Technology, 18*(1), 226–232.

[66] 66. Iqbal, M., & Salazar, L. A. (2025). Epigenetic repurposing of carbohydrate metabolic inhibitors for insulin resistance: Targeting DNMT1 and HDAC3 for β-cell restoration. *Frontiers in Epigenetics and Epigenomics, 3*.

[67] 67. Sun, L., & Miao, M. (2019). Dietary polyphenols modulate starch digestion and glycaemic level: A review. *Critical Reviews in Food Science and Nutrition, 60*(4), 541–555.

[68] 68. Pascale, R., Bianco, G., Cataldi, T. R. I., Schmitt-Kopplin, P., Bosco, F., Vignola, L., Uhl, J., Lucio, M., & Milella, L. (2017). Mass spectrometry-based phytochemical screening for hypoglycemic activity of Fagioli di

Sarconi beans (*Phaseolus vulgaris* L.). *Food Chemistry, 242*, 497–504.

[69] 69. Li, X., Bai, Y., Jin, Z., & Svensson, B. (2021). Food-derived non-phenolic α-amylase and α-glucosidase inhibitors for controlling starch digestion rate and guiding diabetes-friendly recipes. *LWT, 153*, 112455.

[70] 70. Rao, V. R., Mans, D. R. A., & Rao, L. (2019). *Phytochemicals in human health*. IntechOpen.

[71] 71. Aboelenin, M. M., Darwish, H., Eshak, M. G., Farag, I., Saqallah, F. G., Almashhadani, A. Q., Al-Najjar, B. O., Wahab, H. A., Baldo, D. E. B., Candelaria, P., Baleta, F. N., Love, J., Baleta, M., Navarro, L. T., Kepok, T., Explants, M., Nurzaman, N., Permadi, T., Setiawati, R., … Desy, A. (2022). *Jordan Journal of Biological Sciences, 15*(5). [Note: Article title not provided in original citation.]

[72] 72. Dewangan, H., Tiwari, R. K., Sharma, V., Shukla, S. S., Satapathy, T., & Pandey, R. K. (2017). Past and future of in-vitro and in-vivo animal models for diabetes: A review. *Indian Journal of Pharmaceutical Education and Research, 51*.

[73] 73. Nada, A. A., Metwally, A. M., Asaad, A. M., Çelik, İ., Ibrahim, R. S., & Eldin, S. M. S. (2024). Synergistic effect of potential alpha-amylase inhibitors from Egyptian propolis with acarbose using in silico and in vitro combination analysis. *BMC Complementary Medicine and Therapies, 24*(1), 65.

[74] 74. Coronado-Olano, J., Repo-Carrasco-Valencia, R., Reátegui, O., Toscano, E., Valdez, E., Zimic, M., & Best, I. (2021). Inhibitory activity against α-amylase and α-glucosidase by phenolic compounds of guinoa (*Chenopodium quinoa* Willd.) and cañihua (*Chenopodium pallidicaule* Aellen) from the Andean region of Peru. *Pharmacognosy Journal, 13*(4), 896–901.

[75] 75. Christopher, A., & Shetty, K. (2024). Phytochemicals-linked food safety and human health protective benefits of the selected food-based botanicals. *PLoS ONE, 19*(7).

[76] 76. Jameel, S., Hameed, A., & Shah, T. (2021). Biochemical profiling for antioxidant and therapeutic potential of Pakistani chickpea (*Cicer arietinum* L.) genetic resource. *Frontiers in Plant Science, 12*, 663623.

[77] 77. Rasheed, M. U., Rashid, H., Iman, S., Oranab, S., Rahim, M. A., Mahmoud, M. H., Castro-Muñoz, R., & Zongo, E. (2025). HPLC, GC-MS, XRD profiling, enzyme inhibition and cytotoxicity potential of *Phlomis stewartii* extracts using response surface methodology. *BMC Plant Biology, 25*(1).

[78] 78. Mony, R. S. (2023). Alpha-glucosidase and alpha-amylase inhibitory activity by polyherbal extract with reference to positive control acarbose. *Journal of Pharmacognosy and Phytochemistry, 12*(2), 11–15.

[79] 79. Mahajan, U. M., Patil, S., Lokhande, S., & Prajakta. (2026). Synergistic potential of polyherbal combinations: An integrative review of phytochemistry and therapeutic applications. *Zenodo*.

[80] 80. Kan, L., Oliviero, T., Verkerk, R., Fogliano, V., & Capuano, E. (2020). Interaction of bread and berry polyphenols affects starch digestibility and polyphenols bio-accessibility. *Socio-Environmental Systems Modeling, 68*, 103924.

[81] 81. Sukardi, S., Damat, D., Fayiz, M., Atoum, M., Zalizar, L., Relawati, R., Jan, A., Vincēviča–Gaile, Z., Warkoyo, W., Abdel-Mawgoud, M., Khedr, F., Mohammed, E., Ahmed, D., Saeed, R., Shakeel, N., Arshad, F., A, Kury, A., Abdoh, L., … L. (2022). Chemical compounds, antioxidant properties, and enzyme inhibitory activities of kitolod leaf and fruit hexane extracts as antidiabetic. *Jordan Journal of Biological Sciences, 15*(5), 897–904.

[82] 82. Akinwunmi, K. F., & Amadi, C. (2019). Assessment of antioxidant and antidiabetic properties of *Picralima nitida* seed extracts. *Journal of Medicinal Plants Research, 13*(1), 9–17.

[83] 83. Ranjan, A., Singh, R. K., Khare, S., Tripathi, R., Pandey, R. K., Singh, A. K., Gautam, V., Tripathi, J., & Singh, S. K. (2019). Characterization and evaluation of mycosterol secreted from endophytic strain of *Gymnema sylvestre* for inhibition of α-glucosidase activity. *Scientific Reports, 9*(1), 17302.

[84] 84. Sudha, P., Zinjarde, S., Bhargava, S., & Kumar, A. R. (2011). Potent α-amylase inhibitory activity of Indian Ayurvedic medicinal plants. *BMC Complementary and Alternative Medicine, 11*(1), 5.

[85] 85. Bahtiarsyah, A. A., Hidayati, L., Wijayanti, N., & Nuringtyas, T. R. (2023). Synergistic activity of *Cinnamomum burmannii* (Nees & T. Nees) Blume and *Aquilaria malaccensis* Lamk. extracts for antidiabetic study. *The Indonesian Biomedical Journal, 15*(2), 132–140.

[86] 86. K., O. A., Makky, E. A., Tawfiq, A. A., Kasturi, M., & Zamri, N. (2020). Evaluating the effect of combined plant extracts on α-amylase and α-glucosidase inhibition activity as antidiabetic agents. *Pakistan Journal of Biological Sciences, 23*(3), 287–294.

[87] 87. Murshed, M., Al-Tamimi, J., & Al-Quraishy, S. (2025). In vitro comparative study of enzyme inhibitory properties of herbal plants and their phenolic, tannin, and flavonoid content as natural inhibitors in public health. *Quality Assurance and Safety of Crops & Foods, 17*(4), 77–87.

[88] 88. Liew, S. Y., Sivasothy, Y., Shaikh, N. N., Javaid, K., Isa, D. M., Lee, V. S., Choudhary, M. I., & Awang, K. (2023). Natural α-glucosidase inhibitors from selected medicinal plants in Malaysia. *Journal of the National Science Foundation of Sri Lanka, 51*(2).

[89] 89. Khadayat, K., Marasini, B. P., Gautam, H., Ghaju, S., & Parajuli, N. (2020). Evaluation of the alpha-amylase inhibitory activity of Nepalese medicinal plants used in the treatment of diabetes mellitus. *Clinical Phytoscience, 6*(1).

[90] 90. Kalita, D., Holm, D. G., LaBarbera, D. V., Petrash, J. M., & Jayanty, S. S. (2018). Inhibition of α-glucosidase, α-amylase, and aldose reductase by potato polyphenolic compounds. *PLoS ONE, 13*(1).

[91] 91. Zeng, L., Zhang, G., Lin, S., & Gong, D. (2016). Inhibitory mechanism of apigenin on α-glucosidase and synergy analysis of flavonoids. *Journal of Agricultural and Food Chemistry, 64*(37), 6939–6949.

[92] 92. Tang, H., Zhao, D., & Xue, Z. (2018). Exploring the interaction between *Salvia miltiorrhiza* and α-glucosidase: Insights from computational analysis and experimental studies. *RSC Advances, 8*(44), 24701–24710.

[93] 93. Kehinde, O. A.-Q., Damilare, B. I., Ogunlana, A., Ayoola, A. M., Emmanuel, A. O., & Isaac, A. T. (2022). Inhibitors of α-glucosidase and angiotensin-converting enzyme in the treatment of type 2 diabetes and its complications: A review on in silico approach. *Pharmaceutical and Biomedical Research, 8*(4), 237–258.

[94] 94. Jenkins, D. J. A., Taylor, R. H., Goff, D. V., Fielden, H., Misiewicz, J. J., Sarson, D. L., Bloom, S. R., & Alberti, K. G. M. M. (1981). Scope and specificity of acarbose in slowing carbohydrate absorption in man. *Diabetes, 30*(11), 951–954.

[95] 95. Dehghan-Kooshkghazi, M., & Mathers, J. C. (2004). Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the α-glucosidase inhibitor acarbose. *British Journal of Nutrition, 91*(3), 357–365.

[96] 96. Peddio, S., Lorrai, S., Padiglia, A., Cannea, F. B., Dettori, T., Cristiglio, V., Genovese, L., Zucca, P., & Rescigno, A. (2023). Biochemical and phylogenetic analysis of Italian *Phaseolus vulgaris* cultivars as sources of α-amylase and α-glucosidase inhibitors. *Plants, 12*(16), 2918.

[97] 97. Rasheed, M. U., Naqvi, S. A. R., Al-Asmari, F., Rahim, M. A., & Ramadan, M. F. (2024). Phytochemicals, health-promoting effects, and enzyme inhibition traits of *Phlomis stewartii* extracts. *Molecules, 29*(5), 1049.

[98] 98. Chonsut, P., Chaniad, P., Limcharoen, T., Rais, I. R., & Sangkaew, S. (2025). Antidiabetic potential of five flower remedy: A Thai traditional remedy with α-amylase and α-glucosidase inhibition, synergistic interactions, and mechanistic insights. *Scientifica, 2025*(1), 5516791.

[99] 99. Maser, W. H., Venkatachalam, K., Kumar, A., Karuturi, S., Bavisetty, S. C. B., & Ali, A. M. M. (2023). Selective green leafy vegetables and their synergistic combination approach as natural anti-diabetic agents: Therapeutic potential. *Research Square*. [Preprint]

[100] 100. Zhang, B., Li, X., Sun, W., Xing, Y., Xiu, Z., Zhuang, C., & Dong, Y. (2017).

Dietary flavonoids and acarbose synergistically inhibit α-glucosidase and lower postprandial blood glucose. *Journal of Agricultural and Food Chemistry, 65*(38), 8319–8330.

[101] 101. Zhu, X., Yan, K., Ye, X., Xiang, X., Ru, Y., Niu, Y., Liu, Y., Xi, J., & Liu, K. (2025). Polyphenols from *Flos Trollii* inhibit α-amylase and α-glucosidase: Kinetic analysis and mechanistic insights. *LWT, 225*, 117940.

[102] 102. Yang, X., Wang, Y., Li, J., Tai, Y., Yang, K., Lv, J., Sun, J., & Zhang, H. (2024). From waste to wonder: Exploring the hypoglycemic and antioxidant properties of corn processing by-products. *Frontiers in Chemistry, 12*, 1433501.

[103] 103. Alem, M. B., Desalegn, T., Demissie, T. B., Belayneh, A., Endale, M., & Eswaramoorthy, R. (2021). Pharmacokinetics and drug-likeness of antidiabetic flavonoids: Molecular docking and DFT study. *PLoS ONE, 16*(12).

[104] 104. Benouchenne, D., Djeghim, H., Benslama, O., Alsaeedi, H., Cornu, D., Bechelany, M., & Barhoum, A. (2025). Antidiabetic potential of peanut oil: Inhibiting α-amylase and α-glucosidase using identified phytochemicals through in vitro and in silico studies. *Frontiers in Nutrition, 12*, 1592468.

[105] 105. Rakotondrabe, T. F., Fan, M., & Guo, M. (2022). Exploring potential antidiabetic and anti-inflammatory flavonoids from *Euphorbia humifusa* with an integrated strategy. *Frontiers in Pharmacology, 13*, 980945.

[106] 106. Sharma, P., Joshi, T., Joshi, T., Chandra, S., & Tamta, S. (2020). Molecular dynamics simulation for screening phytochemicals as α-amylase inhibitors from medicinal plants. *Journal of Biomolecular Structure and Dynamics, 39*(17), 6524–6538.

[107] 107. Abchir, O., Rossafi, B., Touti, R., Yamari, I., Abass, K. S., Samadi, A., & Chtita, S. (2025). Structure-guided identification of novel natural antidiabetic inhibitors: Targeting glucoamylase from *Saccharomycopsis fibuligera*. *Scientific African, 31*.

[108] 108. Pan, J., Nawaz, M., Liu, J., Liu, H., Lv, Z., Yang, W., Jiao, Z., & Zhang, Q. (2024). Exploring synergistic inhibitory mechanisms of flavonoid mixtures on α-glucosidase by experimental analysis and molecular dynamics simulation. *Food Chemistry, 464*, 141560.

[109] 109. Salehi, P., Asghari, B., Esmaeili, M. A., Dehghan, H., & Ghazi, I. (2013). α-Glucosidase and α-amylase inhibitory effect and antioxidant activity of ten plant extracts traditionally used in Iran for diabetes. *Journal of Medicinal Plants Research, 7*(6), 257–266.

[110] 110. Tang, H., Huang, L., Sun, C., & Zhao, D. (2020). Exploring the structure–activity relationship and interaction mechanism of flavonoids and α-glucosidase based on experimental analysis and molecular docking studies. *Food & Function, 11*(4), 3332–3350.

[111] 111. Sadeghi, M., Miroliaei, M., Rahimmalek, M., Taslımı, P., Szumny, A., & Sadeghian, N. (2023). Comparison of flavonoid and flavonoid glycoside in the inhibition of the starch hydrolyzing enzymes and AGEs: A virtual approach. *Journal of Oleo Science, 72*(8), 787–797.

[112] 112. Wang, Y., An, J., Yao, S., Zhang, C., Zhou, Y., Li, L., & Li, H. (2025). Effect of sugarcane polyphenol extract on α-amylase inhibition and mechanism exploration. *Foods, 14*(13), 2174.

[113] 113. Ayorinde, A. I., Esosa, I. V., Adebayo, S. O., Nokwanda, D. H., Fadele, L., & Oyawaluja, B. O. (2025). Molecular docking, ADME and SAR analysis of 383 phytochemicals in the quest for lead antidiabetic inhibitors targeting α-amylase and α-glucosidase enzymes. *Tropical Journal of Drug Research, 2*(1), 6.

[114] 114. Yang, T., Yang, Z., Pan, F., Jia, Y., Cai, S., Zhao, L., Zhao, L., Zhao, L., Zhao, L., Wang, O., & Wang, C. (2022). Construction of an MLR-QSAR model based on dietary flavonoids and screening of natural α-glucosidase inhibitors. *Foods, 11*(24), 4046.

[115] 115. Rubio-Senent, F., Bermúdez-Oria, A., Lama-Muñoz, A., Rodríguez-Gutiérrez, G., & Fernández-Bolaños, J. (2025). Synergistic inhibition of α-glucosidase and α-amylase by phenolic compounds isolated from olive oil by-products. *Journal of the Science of Food and Agriculture, 105*(13), 7591–7597.

[116] 116. Lacroix, I. M. E., & Li-Chan, E. C. Y. (2016). Food-derived dipeptidyl-peptidase IV inhibitors as a potential approach for glycemic regulation – Current knowledge and future research considerations. *Trends in Food Science & Technology, 54*, 1–16.

[117] 117. Nie, T., & Cooper, G. J. S. (2021). Mechanisms underlying the antidiabetic activities of polyphenolic compounds: A review. *Frontiers in Pharmacology, 12*, 798329.

[118] 118. Shahidi, F., & Dissanayaka, C. S. (2023). Phenolic-protein interactions: Insight from in-silico analyses – A review. *Food Production, Processing and Nutrition, 5*(1).